| HOME >> BIOLOGY >> TECHNOLOGY |
The principle behind using 5-FU on a CVC is that the drug appears to effectively interrupt the colonization of an implanted medical device by those micro-organisms that typically gain entrance to the bloodstream via the local skin penetration of implanted catheters. This reduction in colonization by bacteria may have a net effect of reducing biofilm burden on the implanted catheters, making them less likely to serve as reservoirs for additional infection.
Note on Forward Looking Statements
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the
words "believes," "may," "could", "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and constitute "forward-looking
information" within the meaning of applicable Canadian securities laws. All
such statements are made pursuant to the "safe harbor" provisions of
applicable securities legislation. Forward-looking statements may involve,
but are not limited to, comments with respect to our objectives and
priorities for 2007 and beyond, our strategies or future actions, our
targets, our estimation of potential market size, expectations for our
financial condition and the results of, or outlook for, our operations,
research development and further product and drug development. Such
forward-looking statements also involve known and unknown risks,
uncertainties and other factors that may cause the actual results
'/>"/>
| SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |